General Characteristics
Age: <20 years
Gender: Male
Disease Origin: Clival
Disease Status: Primary
Prior Radiation: No
Prior Systemic Therapy: No
Source: Dr. Mark Prince and John Henry Owen, University of Michigan
Notes: This cell line was developed from the same tumor as the CF459 PDX model. The UM-Chor5 series is a progression model from the same patient; UM-Chor5 is derived from the primary clival tumor at initial diagnosis.
Molecular Features
Cell Morphology: Physaliferous
TBXT Expression: Positive; 2x that of U-CH2
TBXT Localization: Nuclear
CD24 Expression: Positive; 1.5x that of U-CH2
HLA Type:
Sequence Data: WES and transcriptome data available: raw sequencing data in Cavatica (Chordoma Foundation Dataset) and summary data in PedcBioportal. Contact researchteam@chordoma.org with any questions.
SMARCB1 Status: Truncating mutation (Lys16*)
Validation Results: Validation Report
Growth Conditions
Growth Medium: (4:1) IMDM/RPMI 1640 + 10% FBS + 1% NEAA + 1% GlutaMAX
Freeze Medium: 70% complete growth medium supplemented with an additional 20% fetal bovine serum and 10% DMSO
Culture Conditions: Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing Instructions: Cell Culture Procedures
Publications
Characterized By:
- Not yet published